Literature DB >> 6190711

Natural cytotoxicity in malignant and premalignant cervical neoplasia and enhancement of cytotoxicity with interferon.

V Seltzer, A Doyle, A S Kadish.   

Abstract

Natural cytotoxicity was measured in 70 women with cervical dysplasia or invasive cervical cancer and in 13 controls, using a short-term chromium release assay. A significant diminution in mean cytotoxicity was found in women with CIN III and with advanced cervical carcinoma. When the peripheral blood leukocytes of patients and controls were pretreated with interferon, there was significant enhancement of the mean cytotoxicity for all groups except those with advanced cervical carcinoma (stage IIB or worse). Our results have shown a significant defect in a potentially important immune surveillance mechanism in a group of patients with premalignant disease at risk for the development of invasive cancer. A possible role for interferon in the treatment of cervical intraepithelial neoplasia is suggested.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190711     DOI: 10.1016/0090-8258(83)90051-3

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Natural killer and antibody-dependent cellular cytotoxicity in cervical carcinoma patients.

Authors:  M N Satam; J N Suraiya; J J Nadkarni
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Depressed level of natural killer cells in cancer family syndrome.

Authors:  G Guanti; S Massari; G Cristofaro; M L Caruso; R Porsia; A Stella; F Susca; A Tauro; I Giorgio
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Natural killer cell activity in patients with pernicious anemia.

Authors:  J A Vargas; M Alvarez-Mon; L Manzano; A Albillos; A Fernández-Corugedo; J C Gea-Banacloche; F M Gonzalez; A Durántez
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

4.  CAM and NK Cells.

Authors:  Kazuyoshi Takeda; Ko Okumura
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.